To compare the efficacy, tolerability and patient acceptability of Allopurinol and Febuxostat in Hyperuricemic Patients.

Abstract

Objectives: To assess the improvement, safety and tolerability of Allopurinol 300mg/daily & Febuxostat 80mg/daily in hyperuricemic patients. Study Design: Clinical Interventional Study. Setting: Medical OPD, Dr. Ruth K M Pfau Civil Hospital Karachi. Period: From September 2018 to March 2019. Material & Methods: The designed interventional study from the Department of Pharmacology Hamdard College of Medicine & Dentistry, approved by BASR & Ethical Review Board of Hamdard University Karachi. Initially 70 enrolled patients, 60-patients of sUA>6.8 mg/dl were registered, after fulfilled the inclusion and exclusion criteria and written consent, detail history on pro forma and biochemical assessments (sUA, S. Creatinine, Alkaline Phosphate, SGPT, Cholesterol, HDL, LDL and Blood sugar were measured at day 0), repeated at day 30, 60 and 90, keep in case record file, on follow up visits for final analysis. Group A, (Allopurinol) & B (Febuxostat) results data were compared of sUA, S. Creatinine and biochemical assessments, to estimate the improvement, safety and tolerability of the drugs. Results: Group-A baseline uric acid were, mean 8.79 ± 0.98 to mean 6.40 ± 0.86 with percentage change was 26%. Group-B treated sUA were changed mean 8.85±0.97 to 5.96±0.68 with percentage change was 33%. Overall improvement in mean was statistically highly significant. Mean difference ± SD for change of serum uric acid in Group-A is 2.39±1.15 with Group-B mean change is 2.90±0.87. Drug safety was determined by adverse effects and blood assay of follow up at day-90 from baseline. Conclusion: Improvement reported by mean of reduced uric acid & no serious adverse effects, results are highly significant.